146 related articles for article (PubMed ID: 38330767)
41. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
[TBL] [Abstract][Full Text] [Related]
42. Molecular Profiling of Endometrial Cancer: An Exploratory Study in Aotearoa, New Zealand.
Henry CE; Phan K; Orsman EJ; Kenwright D; Thunders MC; Filoche SK
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830795
[TBL] [Abstract][Full Text] [Related]
43. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
[TBL] [Abstract][Full Text] [Related]
44. Prognostic role of transcription factor
Onoprienko A; Hofstetter G; Muellauer L; Dorittke T; Polterauer S; Grimm C; Bartl T
Int J Gynecol Cancer; 2024 Jun; 34(6):840-846. PubMed ID: 38508586
[TBL] [Abstract][Full Text] [Related]
45. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
46. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
[No Abstract] [Full Text] [Related]
47. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
48. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
[TBL] [Abstract][Full Text] [Related]
49. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
[TBL] [Abstract][Full Text] [Related]
50. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Whelan K; Dillon M; Strickland KC; Pothuri B; Bae-Jump V; Borden LE; Thaker PH; Haight P; Arend RC; Ko E; Jackson AL; Corr BR; Ayoola-Adeola M; Wright JD; Podwika S; Smitherman C; Thomas S; Lightfoot M; Newton M; Washington C; Mullen M; Cosgrove C; Harsono AAH; Powell K; Herzog TJ; Salani R; Alvarez Secord A
Gynecol Oncol; 2023 Nov; 178():44-53. PubMed ID: 37748270
[TBL] [Abstract][Full Text] [Related]
51. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
52. Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomas.
Pain FA; Beinse G; Azaïs H; Auvray-Kuentz M; Garcin LM; Delanoy N; Bentivegna E; Benoit L; Nguyen-Xuan HT; Blons H; Fabiano E; LE Frère Belda MA; Bats AS; Koual M
Eur J Surg Oncol; 2023 Sep; 49(9):106954. PubMed ID: 37349159
[TBL] [Abstract][Full Text] [Related]
53. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
54. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
55. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
56. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
[TBL] [Abstract][Full Text] [Related]
57. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
[TBL] [Abstract][Full Text] [Related]
58. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
[TBL] [Abstract][Full Text] [Related]
59. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
60. Clear cell carcinoma of the endometrium.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Lorusso D; Coleman R; Vaughan MM; Takano M; Provencher D; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Kim JW; Candido Dos Reis FJ; Mariani A; Leitao MM; Makker V; Rustum NA; Vergote I; Zannoni GF; Tan DSP; McCormack M; Bini M; Lopez S; Raspagliesi F; Panici PB; di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2022 Mar; 164(3):658-666. PubMed ID: 35063279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
